UK Rejects Lilly’s Portrazza

Source: The Pharma Letter

May 26, 2016

The National Institute for Health and Care Excellence (NICE) has not recommended approval of Eli Lilly’s Portrazza lung cancer treatment for use in the National Health Service.

While the committee acknowledged that Portrazza provides small improvements in overall survival, they said it cost too much compared to combination chemotherapy.

The treatment would cost between $110,000-170,000 per quality-adjusted life year gained.

Read the Pharma Letter coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments